

Lao People's Democratic Republic

Tuberculosis profile

Population 2016

6.8 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	2.9 (1.7–4.4)	43 (25–65)
Mortality (HIV+TB only)	0.34 (0.21–0.5)	5.1 (3.1–7.5)
Incidence (includes HIV+TB)	12 (7.7–17)	175 (113–250)
Incidence (HIV+TB only)	0.71 (0.45–1)	11 (6.7–15)
Incidence (MDR/RR-TB)**	0.72 (0.33–1.1)	11 (4.8–17)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.75 (0.46–1)	3.1 (1.9–4.3)	3.8 (2.3–5.4)
Males	0.85 (0.52–1.2)	7.1 (4.3–9.9)	8 (4.9–11)
Total	1.6 (0.97–2.2)	10 (6.2–14)	12 (7.7–17)

TB case notifications, 2016

Total cases notified	5 012
Total new and relapse	4 981
- % tested with rapid diagnostics at time of diagnosis	47%
- % with known HIV status	91%
- % pulmonary	92%
- % bacteriologically confirmed among pulmonary	81%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	42% (29–65)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.29 (0.14–0.46)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	275	6%
- on antiretroviral therapy	205	75%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			260 (150–380)
Estimated % of TB cases with MDR/RR-TB	5.5% (3–8)	12% (7.2–19)	
% notified tested for rifampicin resistance	46%	85%	2 342
MDR/RR-TB cases tested for resistance to second-line drugs		12	
Laboratory-confirmed cases		MDR/RR-TB: 44, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 33, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	88%	4 547
Previously treated cases, excluding relapse, registered in 2015	85%	107
HIV-positive TB cases registered in 2015	63%	284
MDR/RR-TB cases started on second-line treatment in 2014	67%	27
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	50%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	31% (28–34)

TB financing, 2017

National TB budget (US\$ millions)	2.3
Funding source: 7% domestic, 93% international, 0% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

